Finally, different molecular markers have low or high expression in Type I vs. Type II ovarian carcinomas, but are rarely totally expressed (PTEN mutation, PIK3CA, KRAS mutation, BRAF mutation) or totally absent in either Type I or Type II EOCs. Here, KRAS is linked to ovarian carcinoma.